標(biāo)題: Titlebook: Antirheumatic Therapy: Actions and Outcomes; Richard O. Day,Daniel E. Fürst,Barry Bresnihan Book 2005 Birkh?user Basel 2005 Arthritis.auto [打印本頁(yè)] 作者: Reagan 時(shí)間: 2025-3-21 18:01
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes影響因子(影響力)
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes被引頻次
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes被引頻次學(xué)科排名
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes年度引用
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes年度引用學(xué)科排名
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes讀者反饋
書(shū)目名稱(chēng)Antirheumatic Therapy: Actions and Outcomes讀者反饋學(xué)科排名
作者: 口味 時(shí)間: 2025-3-21 22:54
Progress in Inflammation Researchhttp://image.papertrans.cn/a/image/158659.jpg作者: 慢跑鞋 時(shí)間: 2025-3-22 00:28
Multiscale , Modeling of Cartilage Injuriesll drugs, the chemical properties of the DMARD and corticosteroids are important aspects of their pharmacology. In this chapter, the medicinal chemistry of the various DMARD is discussed. The coverage includes the chemical factors that affect their handling by the body. In addition to the DMARD disc作者: 到婚嫁年齡 時(shí)間: 2025-3-22 04:39
Brianne K. Connizzo,Lin Han,Robert L. Sahheir patients are faced with a variety of therapeutic choices in the management of RA and must make decisions about specific disease-modifying antirheumatic drugs (DMARDs), including potential combinations of different agents. A careful balance of short-term and long-term benefits and risks must be 作者: NAVEN 時(shí)間: 2025-3-22 09:10 作者: 委屈 時(shí)間: 2025-3-22 13:54
https://doi.org/10.1007/978-3-319-48899-8ponse. However, biologic agents are frequently immunogenic, requiring complex and labor intensive production processes and parenteral administration, resulting in high costs which limit both availability and access to treatment.作者: 未開(kāi)化 時(shí)間: 2025-3-22 19:04 作者: EVICT 時(shí)間: 2025-3-23 00:35 作者: 致敬 時(shí)間: 2025-3-23 02:52 作者: 無(wú)力更進(jìn) 時(shí)間: 2025-3-23 07:22
Advances in Applied Neurological Sciences 6-mercaptopurine and this is metabolised by hypoxanthine guanine phosphoribosyl transferase (HGPRT) to produce the active metabolites thioinosinic and thioguanylic acid. These metabolites inhibit intracellular function by interfering with adenine and guanine ribonucleotide production through suppre作者: 樹(shù)膠 時(shí)間: 2025-3-23 11:13 作者: Sleep-Paralysis 時(shí)間: 2025-3-23 17:19
Advances in Applied Neurological Sciencesd to other currently available immunomodulatory agents and was first evaluated in experimental models of autoimmune disease and post-transplant graft . host disease. Its action as an anti-inflammatory and immunomodulatory drug has been applied to the treatment of rheumatoid arthritis (RA) in both . 作者: 不能強(qiáng)迫我 時(shí)間: 2025-3-23 18:46 作者: HEW 時(shí)間: 2025-3-23 23:19 作者: 鴿子 時(shí)間: 2025-3-24 02:24
https://doi.org/10.1007/978-1-4757-3205-4sfully treat a patient with rheumatoid arthritis (RA) [., .]. Over the intervening years, opinions about glucocorticoids have varied from excitement to complete rejection. Most of the worries concerning their use have been about adverse effects. Despite this historical variability in rheumatological作者: 場(chǎng)所 時(shí)間: 2025-3-24 06:51 作者: tackle 時(shí)間: 2025-3-24 10:41
Electron-Specimen Interactions, receptor antagonist (IL-IRa) [.], Extracellular IL-lα, which is membrane-associated, and IL- lβ, which is the soluble form, are agonist molecules that can influence the functions of most cell types. Activated monocytes and macrophages are the principal source of IL-la and IL-lβ. There are two disti作者: deactivate 時(shí)間: 2025-3-24 16:03
Introduction to Electron Beam Instruments,th a chronic disabling disease that only rarely exhibits a sustained treatment-induced remission. As new treatments have been developed, they have been tried and added to existing therapies [.]. Narcotic analgesics were supplemented with salicylates, and later with corticosteroids. Early disease mod作者: Water-Brash 時(shí)間: 2025-3-24 20:07 作者: 召集 時(shí)間: 2025-3-25 03:07 作者: TAIN 時(shí)間: 2025-3-25 05:14
Electron Beam Testing TechnologyIn humans, autoimmune diseases (ADs) represent a heterogeneous group of disorders with diverse genetic and environmental etiological factors.作者: Systemic 時(shí)間: 2025-3-25 10:58 作者: Commemorate 時(shí)間: 2025-3-25 13:30 作者: calorie 時(shí)間: 2025-3-25 19:12 作者: 極深 時(shí)間: 2025-3-25 23:16 作者: larder 時(shí)間: 2025-3-26 01:50
Medicinal chemistry of the disease modifying anti-rheumatic drugs,ussed in this book, the chemistry of penicillamine is also described. Although the use of penicillamine as an anti-rheumatic drug has declined in recent years, thiol compounds, such as penicillamine, are still of great interest because of their antioxidant activity and potential activities in inflammatory states.作者: 金桌活畫(huà)面 時(shí)間: 2025-3-26 05:40
Systemic glucocorticoids in rheumatoid arthritis, opinion, many patients in practice are prescribed glucocorticoids. Here we review new evidence on the mechanisms of action of glucocorticoids, outcomes of glucocorticoid treatment and adverse effects, and propose an evidence based approach to their effective use in the management of rheumatoid arthritis.作者: MELON 時(shí)間: 2025-3-26 10:48
,TNF-α inhibitors,NF from stimulating the cell to produce the biochemical agents that are ultimately responsible for the clinical markers of RA: inflammation, tissue damage, pain, stiffness, swelling, tenderness, and eventual deformation of the joint and patient disability.作者: OVERT 時(shí)間: 2025-3-26 13:10 作者: 駭人 時(shí)間: 2025-3-26 18:38
https://doi.org/10.1007/978-981-4451-21-5t of that disease, highlighted by Pelletier and Caventou’s isolation of quinine and cinchonine as active antimalarial agents in 1820. Quinacrine, though not an aminoquinolone, carries within it the imbedded structure of chloroquine.作者: 蝕刻術(shù) 時(shí)間: 2025-3-26 22:37 作者: Suggestions 時(shí)間: 2025-3-27 03:13 作者: 俗艷 時(shí)間: 2025-3-27 05:26 作者: Myosin 時(shí)間: 2025-3-27 10:37 作者: noxious 時(shí)間: 2025-3-27 14:06 作者: conjunctiva 時(shí)間: 2025-3-27 19:13 作者: Oration 時(shí)間: 2025-3-27 23:28 作者: packet 時(shí)間: 2025-3-28 04:18
Azathioprine,d thioguanylic acid. These metabolites inhibit intracellular function by interfering with adenine and guanine ribonucleotide production through suppression of inosinic acid synthesis [.. These effects result in downregulation of actively proliferating cells with a particular effect on bone marrow.作者: 不持續(xù)就爆 時(shí)間: 2025-3-28 09:45
Methotrexate, cytotoxic effect on proliferating lymphocytes. Subsequently its efficacy in RA was proven in a series of papers in the mid 1980s and it is now the mainstay of RA therapy, both alone and in combination, as recommended in the guidelines of the American College of Rheumatology 2002 [.].作者: mechanism 時(shí)間: 2025-3-28 12:55 作者: 的’ 時(shí)間: 2025-3-28 15:18 作者: 熔巖 時(shí)間: 2025-3-28 19:00
https://doi.org/10.1007/978-1-4757-3205-4 opinion, many patients in practice are prescribed glucocorticoids. Here we review new evidence on the mechanisms of action of glucocorticoids, outcomes of glucocorticoid treatment and adverse effects, and propose an evidence based approach to their effective use in the management of rheumatoid arthritis.作者: 共同確定為確 時(shí)間: 2025-3-29 02:11
Gregory S. Rohrer,Valerie RandleNF from stimulating the cell to produce the biochemical agents that are ultimately responsible for the clinical markers of RA: inflammation, tissue damage, pain, stiffness, swelling, tenderness, and eventual deformation of the joint and patient disability.作者: 薄膜 時(shí)間: 2025-3-29 03:52
Electromigration Inside Logic Cellsuently referred to as “investments” to maintain a healthy and productive workforce [.]. Demonstration of “value for money” has become an important milestone for therapies on their way to rapid, and reimbursed, adoption.作者: 禮節(jié) 時(shí)間: 2025-3-29 08:16
Advances in Applied Neurological Scienceseffective in improving symptoms of RA and prevention of radiographic erosions. Like methotrexate or sulfasalazine, which are two commonly used first-line DMARDs, leflunomide has been shown to improve function and quality of life in patients with active RA.作者: 戲服 時(shí)間: 2025-3-29 15:23
H.-M. Meinck,R. Benecke,B. Conradof organ transplant patients was never equalled in rheumatology, but CsA certainly has a place as immunosuppressive agent in the treatment of many autoimmune diseases, especially in rheumatoid arthritis (RA).作者: remission 時(shí)間: 2025-3-29 16:53
Advances in Applied Neurological SciencesAlthough an infectious cause of RA has not been demonstrated, the role of the tetracycline family in treating RA has been re-examined due to the discovery of the anti-inflammatory and immunomodulatory effects of these agents.作者: Merited 時(shí)間: 2025-3-29 21:46
Pharmacoeconomic properties of disease-modifying antirheumatic drugs,uently referred to as “investments” to maintain a healthy and productive workforce [.]. Demonstration of “value for money” has become an important milestone for therapies on their way to rapid, and reimbursed, adoption.作者: tackle 時(shí)間: 2025-3-30 01:17
Leflunomide,effective in improving symptoms of RA and prevention of radiographic erosions. Like methotrexate or sulfasalazine, which are two commonly used first-line DMARDs, leflunomide has been shown to improve function and quality of life in patients with active RA.作者: Fraudulent 時(shí)間: 2025-3-30 06:04
Cyclosporin,of organ transplant patients was never equalled in rheumatology, but CsA certainly has a place as immunosuppressive agent in the treatment of many autoimmune diseases, especially in rheumatoid arthritis (RA).作者: investigate 時(shí)間: 2025-3-30 09:30
Tetracyclines,Although an infectious cause of RA has not been demonstrated, the role of the tetracycline family in treating RA has been re-examined due to the discovery of the anti-inflammatory and immunomodulatory effects of these agents.作者: glowing 時(shí)間: 2025-3-30 13:15
Medicinal chemistry of the disease modifying anti-rheumatic drugs,ll drugs, the chemical properties of the DMARD and corticosteroids are important aspects of their pharmacology. In this chapter, the medicinal chemistry of the various DMARD is discussed. The coverage includes the chemical factors that affect their handling by the body. In addition to the DMARD disc作者: 知道 時(shí)間: 2025-3-30 18:58
Targeting DMARD therapy,heir patients are faced with a variety of therapeutic choices in the management of RA and must make decisions about specific disease-modifying antirheumatic drugs (DMARDs), including potential combinations of different agents. A careful balance of short-term and long-term benefits and risks must be 作者: amyloid 時(shí)間: 2025-3-30 22:07 作者: Diskectomy 時(shí)間: 2025-3-31 02:26 作者: Overthrow 時(shí)間: 2025-3-31 05:09
Hydroxychloroquine,e bark of the Peruvian cinchocha tree. Along with quinacrine, the two aminoquilones are labeled antimalarials after their long history in the treatment of that disease, highlighted by Pelletier and Caventou’s isolation of quinine and cinchonine as active antimalarial agents in 1820. Quinacrine, thou作者: 分開(kāi) 時(shí)間: 2025-3-31 11:47
Sulfasalazine,c drugs based on notions of pathogenesis. She tried to link an antibacterial to an antiinflammatory agent in order to achieve simultaneous elimination of a putative infectious organism causing rheumatoid arthritis (RA) and suppression of inflammation. A number of compounds were developed and the one作者: 恭維 時(shí)間: 2025-3-31 16:43
Parenteral gold, infections and, from the 1920s, also for rheumatoid arthritis (RA), believed to be caused by strep-tococcal infection. In 1935 Forestier reported over 550 cases, of whom 70–80% experienced remission or at least transient inactivation of the disease for 2–3 years, and Hartfall reported a clear impro作者: 脾氣暴躁的人 時(shí)間: 2025-3-31 20:48 作者: 凝視 時(shí)間: 2025-3-31 23:39 作者: 錯(cuò) 時(shí)間: 2025-4-1 02:51
Leflunomide,d to other currently available immunomodulatory agents and was first evaluated in experimental models of autoimmune disease and post-transplant graft . host disease. Its action as an anti-inflammatory and immunomodulatory drug has been applied to the treatment of rheumatoid arthritis (RA) in both .
